Company intelligence / Profile preview

Chengdu Shi Endor Biological Engineering Technology

Chengdu, Sichuan Province, Chinabiotechplaza.com ↗

Ownership: Private
Development stage: Other

Overview

The company is conducting a multicenter, randomized, controlled phase II clinical trial evaluating the anti-tumor efficacy and safety of recombinant human endostatin adenovirus injection combined with chemotherapy in advanced head and neck malignancies. No published results yet; trial is recruiting as of April 2025.

Therapeutic areas: Oncology
Modalities: Gene therapyRecombinant proteinViral vector-based therapy
Industry: Biotech

Beyond the preview

Go deeper on Chengdu Shi Endor Biological Engineering Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chengdu Shi Endor Biological Engineering Technology.

Explore the full profile